February 08, 2011
The plaintiffs' counsel in a shareholder class action against Pfizer Inc. executives over an allegedly fraudulent marketing campaign have asked a judge to sanction $22 million in attorneys' fees as part of the final approval of a $75 million settlement.
December 15, 2010
A federal judge has given an initial blessing to Pfizer Inc.'s proposed $75 million settlement to end a slew of derivative suits lodged against the drugmaker's executives over a marketing campaign that resulted in $2.3 billion in claims.
October 15, 2009
Skandia Life Insurance Co. Ltd. has become the latest party to request lead plaintiff status in a consolidated derivative lawsuit accusing Pfizer Inc. executives of harming the company by promoting prescription drugs for unapproved off-label uses.
October 09, 2009
Institutional investor Amalgamated Bank is competing with an individual shareholder over who will lead a consolidated derivative lawsuit alleging that Pfizer Inc.'s executives harmed the company by promoting prescription drugs for unapproved, off-label uses.
September 11, 2009
The entire board of directors at Pfizer Inc. and certain executives have been smacked with a shareholder derivative lawsuit alleging they harmed the company by promoting prescription drugs for unapproved, off-label uses.